scholarly journals Drug information of Aducanumab and its effectiveness for Alzheimer’s disease: A clinical review

2021 ◽  
Vol 2 (2) ◽  
pp. 072-077
Author(s):  
Neel Sureshbhai Raval ◽  
Sachi Anilkumar Chavda ◽  
Dhwanil Nileshkumar Mithaiwala ◽  
SP Srinivas Nayak ◽  
Mohit Buddhdev ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Monoclonal Antibody ◽  
Clinical Review ◽  
Drug Information ◽  
Clinical Importance ◽  
New Class

Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 million cases per year reported in India. AD and other kinds of dementia are more common as individuals become older, affecting 1 in every 14 people over the age of 65 and 1 in every 6 people over the age of 80. ADUHELM (Aducanumab) is a monoclonal antibody, new class of medication needed for treatment of AD. The latest drug used to treat underlying cause of AD and recent studies shown to be efficacious and safe for the AD. Our review emphasizes on the drug information of Aducanumab and its clinical importance in AD.

A monoclonal antibody Hy20-54-16-3L to lambda (λ) light chain of human immunoglobulin reacts with amyloid in Alzheimer's disease brain

1990 ◽  
Vol 117 (1-2) ◽  
pp. 62-67 ◽  
Author(s):  
Fuyuki Kametani ◽  
Kikuko Tanaka ◽  
Maroto Sato ◽  
Seiichi Haga ◽  
Takashi Saitoh ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Monoclonal Antibody ◽  
Light Chain ◽  
Human Immunoglobulin ◽  
Λ Light Chain

Immunochemical characterization of a monoclonal antibody specific for Alzheimer's disease associated protein

1992 ◽  
Vol 41 (1) ◽  
pp. 111-115
Author(s):  
Angelika Bodenteich ◽  
Lloyd G. Mitchell ◽  
Carl R. Merril ◽  
Barney E. Miller ◽  
Hossein A. Ghanbari ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Monoclonal Antibody ◽  
Immunochemical Characterization

Mild cognitive impairment in primary care: a clinical review

2018 ◽  
Vol 94 (1117) ◽  
pp. 647-652 ◽  
Author(s):  
Georges Assaf ◽  
Maria Tanielian
Keyword(s):  
Alzheimer’S Disease ◽  
Primary Care ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Clinical Review ◽  
Primary Care Physicians ◽  
Early Recognition ◽  
Neuropsychiatric Symptoms ◽  
Evidenced Based

Dementia is projected to become a global health priority but often not diagnosed in its earlier preclinical stage which is mild cognitive impairment (MCI). MCI is generally referred as a transition state between normal cognition and Alzheimer’s disease. Primary care physicians play an important role in its early diagnosis and identification of patients most likely to progress to Alzheimer’s disease while offering evidenced-based interventions that may reverse or halt the progression to further cognitive impairment. The aim of this review is to introduce the concept of MCI in primary care through a case-based clinical review. We discuss the case of a patient with MCI and provide an evidence-based framework for assessment, early recognition and management of MCI while addressing associated risk factors, neuropsychiatric symptoms and prognosis.

Sign in / Sign up

Export Citation Format

Share Document